GeneOne Life Science, Inc. (KRX:011000)
South Korea · Delayed Price · Currency is KRW 2,015.00
+48.00 (2.44%)
Feb 5, 2026, 3:30 PM KST
GeneOne Life Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -51,362 | -48,537 | -77,768 | -38,150 | -15,888 | -18,648 |
Depreciation & Amortization | 18,193 | 17,961 | 12,776 | 5,424 | 4,650 | 4,021 |
Loss (Gain) From Sale of Assets | -40.38 | -2.82 | -3.4 | -1.31 | 106.64 | - |
Asset Writedown & Restructuring Costs | - | - | 32,309 | - | - | - |
Loss (Gain) From Sale of Investments | 5.54 | 4.25 | - | - | - | - |
Provision & Write-off of Bad Debts | -56.47 | 2.7 | -845.52 | 1,293 | 111.17 | -174.13 |
Other Operating Activities | 13,692 | 8,442 | 3,171 | 3,579 | -2,084 | 1,219 |
Change in Accounts Receivable | 2,029 | 407.86 | 4,835 | -2,848 | 68.06 | 1,672 |
Change in Inventory | 694.58 | -2,096 | -207.63 | -4,256 | -2,415 | 409.55 |
Change in Accounts Payable | 4,864 | 10,240 | 3,801 | -10,003 | 10,610 | 4,529 |
Change in Income Taxes | -36.75 | - | - | - | -97.74 | -67.04 |
Change in Other Net Operating Assets | -2,952 | -1,987 | 188.33 | 20,850 | -194.83 | -8,908 |
Operating Cash Flow | -15,462 | -16,058 | -21,744 | -24,113 | -4,849 | -15,916 |
Capital Expenditures | -1,657 | -3,298 | -5,601 | -45,306 | -82,442 | -16,153 |
Sale of Property, Plant & Equipment | 44.03 | 2.12 | 15.7 | - | 29.13 | - |
Sale (Purchase) of Intangibles | -44.09 | -69.14 | -51.59 | -101.81 | -75.24 | -216.6 |
Investment in Securities | -111.37 | 470.79 | 31,529 | 53,000 | -57,000 | -27,536 |
Other Investing Activities | 480 | 46 | -0 | -151.33 | -5,961 | - |
Investing Cash Flow | -1,286 | -2,845 | 25,892 | 8,055 | -146,398 | -44,305 |
Short-Term Debt Issued | - | 1,352 | 3,792 | 701.15 | 1,054 | - |
Long-Term Debt Issued | - | 9,224 | 6,271 | 11,469 | - | 23,520 |
Total Debt Issued | 32,681 | 10,576 | 10,063 | 12,171 | 1,054 | 23,520 |
Short-Term Debt Repaid | - | -506.85 | -2,100 | - | -150.86 | -958.08 |
Long-Term Debt Repaid | - | -2,700 | -18,712 | -5,537 | -1,639 | -10,731 |
Total Debt Repaid | -16,768 | -3,207 | -20,812 | -5,537 | -1,790 | -11,689 |
Net Debt Issued (Repaid) | 15,913 | 7,369 | -10,749 | 6,633 | -735.35 | 11,831 |
Issuance of Common Stock | 1,000 | 3,590 | 2,470 | 382.44 | 112,609 | 94,404 |
Other Financing Activities | -33.09 | -0 | -5.64 | -2.97 | -849.86 | - |
Financing Cash Flow | 16,880 | 10,959 | -8,285 | 7,013 | 111,023 | 106,235 |
Foreign Exchange Rate Adjustments | 14.11 | 13.81 | -13.29 | -3.42 | 101.37 | -503.35 |
Miscellaneous Cash Flow Adjustments | 0 | 0 | - | 0 | 0 | 0 |
Net Cash Flow | 146.26 | -7,931 | -4,150 | -9,049 | -40,122 | 45,510 |
Free Cash Flow | -17,119 | -19,356 | -27,345 | -69,419 | -87,291 | -32,069 |
Free Cash Flow Margin | -55.41% | -54.19% | -68.02% | -142.49% | -225.56% | -77.27% |
Free Cash Flow Per Share | -209.10 | -243.60 | -351.70 | -895.90 | -1175.77 | -531.20 |
Cash Interest Paid | 52.22 | 74.66 | 82.15 | 58.5 | - | 48.96 |
Cash Income Tax Paid | - | -236.05 | 104.9 | 326.55 | 189.71 | - |
Levered Free Cash Flow | 6,315 | 2,211 | -22,581 | -73,691 | -103,116 | -13,891 |
Unlevered Free Cash Flow | 8,054 | 3,558 | -21,843 | -69,123 | -100,332 | -13,498 |
Change in Working Capital | 4,106 | 6,071 | 8,617 | 3,743 | 8,255 | -2,333 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.